[Skip to Content]
[Skip to Content Landing]
July 12, 1976

Medical News

JAMA. 1976;236(2):119-127. doi:10.1001/jama.1976.03270020003001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Purified lung cancer antigen proves useful in immunochemotherapy trial  Immunochemotherapy of lung cancer is approaching the stage of multi-institutional trials, according to investigators in Canada and the United States.Thomas H. M. Stewart, MD, Jules E. Harris, MD, and Ariel C. Hollinshead, MD, made this assertion in Toronto at the meeting of the American Society of Clinical Oncology. They reported on a group of patients whose disease has been controlled for up to 39 months by means of combined therapy using drugs— high dose methotrexate with leucovorin calcium (citrovorum factor) rescue—and inoculation with purified lung cancer antigen. Drs Stewart and Harris are both associate professors of medicine on the Faculty of Medicine of Ottawa University. They treated the patients with antigen prepared by Dr Hollinshead, professor of oncology at George Washington University School of Medicine."Immunochemotherapy—the approach where drugs are used the proper way in combination with immunotherapy—is the